Get the Stockscreener App
376.04
1.22%
4.54
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $376.04, with a volume of 2.45M.
It is up +1.22% in the last 24 hours and up +7.00% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$371.50
Open:
$372.725
24h Volume:
2.45M
Relative Volume:
0.94
Market Cap:
$202.95B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
26.15
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+2.66%
1M Performance:
+7.00%
6M Performance:
+9.08%
1Y Performance:
+21.87%
1-Day Range:
$372.16
$379.41
1-Week Range:
$359.21
$379.41
52-Week Range:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
376.04 | 202.95B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,196.03 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 634.77B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.36 | 458.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.07 | 323.72B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.01 | 294.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (AMGN) Beat Revenue Forecasts, Is The Stock Overvalued? - simplywall.st
Lombard Odier Asset Management Switzerland SA Has $14.53 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by OMERS ADMINISTRATION Corp - MarketBeat
Amgen Inc. $AMGN Shares Sold by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Entropy Technologies LP Buys Shares of 9,161 Amgen Inc. $AMGN - MarketBeat
Gabelli Funds LLC Reduces Stake in Amgen Inc. $AMGN - MarketBeat
Aristotle Atlantic Partners LLC Purchases Shares of 4,000 Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steadily as oncology and cardiovascular pipeline supports long term growth - AD HOC NEWS
Amgen stock trims losses as Repatha data and oncology pipeline support long term growth - AD HOC NEWS
Why MrBeast, Stand Up To Cancer, and Amgen Joined Forces to Support Pediatric Cancer Research - Amgen
Amgen stock trades steadily as investors weigh Repatha growth and recent earnings - AD HOC NEWS
Amgen Inc (AMGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aristotle Capital Management LLC Lowers Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen stock edges higher as KRAS lung cancer data and revenue growth support outlook - AD HOC NEWS
Amgen stock trades steadily as recent earnings and obesity drug pipeline shape outlook - AD HOC NEWS
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos - Reuters
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Amgen stock trades steady as oncology and cardiovascular drugs support outlook - AD HOC NEWS
Amgen Inc. Revenue Breakdown – HAN:AMG - TradingView
Amgen hands in data package in hopes of FDA hearing for Tavneos defense - Fierce Pharma
Amgen submits new data to challenge FDA’s proposal to withdraw Tavneos - 1470 & 100.3 WMBD
Amgen stock trades steady as recent earnings and pipeline updates shape investor focus - AD HOC NEWS
Amgen Says Strongly Disagrees With FDA'S Proposal To Withdraw Tavneos From The U.S. Market - TradingView
Amgen Inc. $AMGN Shares Sold by Oak Associates Ltd. OH - MarketBeat
Public Employees Retirement System of Ohio Grows Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Sei Investments Co. - MarketBeat
Compound Planning Inc. Buys 7,818 Shares of Amgen Inc. $AMGN - MarketBeat
Dickmeyer Boyce Financial Management Inc. Acquires Shares of 2,888 Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steady as biosimilar growth offsets mixed Q1 2026 trends - AD HOC NEWS
Amgen Inc. $AMGN Shares Acquired by Cetera Investment Advisers - MarketBeat
Bank of Nova Scotia Has $110.56 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steady as recent earnings and pipeline progress shape investor view - AD HOC NEWS
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest - Yahoo Finance
What Amgen (AMGN)'s Blocked Colorado Enbrel Price Cap Means For Shareholders - simplywall.st
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? - The Motley Fool
Amgen stock rises on earnings and pipeline progress - Ad-hoc-news.de
Amgen Inc (NASDAQ:AMGN) Shows Technical Strength and Breakout Setup - ChartMill
Amgen stock edges higher as oncology pipeline and restructuring savings shape outlook - Ad-hoc-news.de
Amgen Inc. $AMGN Shares Acquired by NewEdge Wealth LLC - MarketBeat
Amgen Inc. $AMGN Shares Bought by First Trust Advisors LP - MarketBeat
Amgen Inc (AMGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amgen stock holds near record levels as earnings and guidance frame the outlook - Ad-hoc-news.de
AMGN stock rises as 2025 revenue reaches $33.4 billion - Ad-hoc-news.de
Composition or Method? How Amgen and Teva Are Reshaping Drug Patent Strategy - JD Supra
Amgen stock trades steady as oncology and obesity pipeline shapes long term growth - Ad-hoc-news.de
Amgen (AMGN) Settles Lawsuit for $74 Million Over Tax Disclosure Delay - GuruFocus
Working capital per share of Amgen Inc. – BCS:AMGN1 - TradingView
Amgen stock trades steadily as recent results and pipeline shape investor sentiment - Ad-hoc-news.de
PNC Financial Services Group Inc. Buys 24,577 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.22%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):